202 related articles for article (PubMed ID: 1807823)
21. Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis.
Pountain GD; Calvin J; Hazleman BL
Br J Rheumatol; 1994 Jun; 33(6):550-4. PubMed ID: 8205403
[TBL] [Abstract][Full Text] [Related]
22. [A case of giant cell arteritis after prednisolone dose reduction during treatment of polymyalgia rheumatica].
Yamashita M; Aoki A; Kobayashi H; Wakiya M; Nakatsugawa M
Nihon Ronen Igakkai Zasshi; 2023; 60(4):440-447. PubMed ID: 38171762
[TBL] [Abstract][Full Text] [Related]
23. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
Salvarani C; Boiardi L; Macchioni P; Rossi F; Tartoni P; Casadei Maldini M; Mancini R; Beltrandi E; Portioli I
Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440
[TBL] [Abstract][Full Text] [Related]
24. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids.
Bengtsson BA; Malmvall BE
Acta Med Scand; 1981; 209(5):337-45. PubMed ID: 7246269
[TBL] [Abstract][Full Text] [Related]
25. Polymyalgia rheumatica and giant cell arteritis. High dose corticosteroids are recommended.
Ferris J; Lamb R
BMJ; 1995 Aug; 311(7002):455. PubMed ID: 7640613
[No Abstract] [Full Text] [Related]
26. [Polymyalgia rheumatica and giant-cell temporal arteritis].
Tereshchenko IV
Klin Med (Mosk); 2006; 84(8):25-30. PubMed ID: 17087187
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.
Emamifar A; Ellingsen T; Hermann AP; Hess S; Gerke O; Ahangarani Farahani Z; Syrak Hansen P; Jensen Hansen IM; Thye-Rønn P
Sci Rep; 2021 Mar; 11(1):6220. PubMed ID: 33737697
[TBL] [Abstract][Full Text] [Related]
28. Giant cell arteritis and polymyalgia rheumatica: an update.
González-Gay MA; Pina T
Curr Rheumatol Rep; 2015 Feb; 17(2):6. PubMed ID: 25618572
[TBL] [Abstract][Full Text] [Related]
29. Polymyalgia arteritica: a clinical review.
Douglas JG; Ford MJ; Innes JA; Munro JF
Eur J Clin Invest; 1979 Apr; 9(2 Pt 1):137-40. PubMed ID: 111944
[TBL] [Abstract][Full Text] [Related]
30. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis.
Lundberg I; Hedfors E
J Rheumatol; 1990 Oct; 17(10):1340-5. PubMed ID: 2254893
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series.
Adizie T; Christidis D; Dharmapaliah C; Borg F; Dasgupta B
Int J Clin Pract; 2012 Sep; 66(9):906-9. PubMed ID: 22897467
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of giant cell arteritis and polymyalgia rheumatica].
Horvath L; Hellmich B
Z Rheumatol; 2020 Mar; 79(2):175-185. PubMed ID: 32078029
[TBL] [Abstract][Full Text] [Related]
33. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.
Askling J; Klareskog L; Hjalgrim H; Baecklund E; Björkholm M; Ekbom A
Ann Rheum Dis; 2005 Dec; 64(12):1765-8. PubMed ID: 15843445
[TBL] [Abstract][Full Text] [Related]
34. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study.
González-Gay MA; García-Porrúa C; Vázquez-Caruncho M; Dababneh A; Hajeer A; Ollier WE
J Rheumatol; 1999 Jun; 26(6):1326-32. PubMed ID: 10381051
[TBL] [Abstract][Full Text] [Related]
35. An alternate-day corticosteroid regimen in maintenance therapy of giant cell arteritis.
Bengtsson BA; Malmvall BE
Acta Med Scand; 1981; 209(5):347-50. PubMed ID: 7246270
[TBL] [Abstract][Full Text] [Related]
36. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study.
Mackie SL; Hensor EM; Haugeberg G; Bhakta B; Pease CT
Rheumatology (Oxford); 2010 Apr; 49(4):716-22. PubMed ID: 20064872
[TBL] [Abstract][Full Text] [Related]
37. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients).
Delecoeuillerie G; Joly P; Cohen de Lara A; Paolaggi JB
Ann Rheum Dis; 1988 Sep; 47(9):733-9. PubMed ID: 3178314
[TBL] [Abstract][Full Text] [Related]
38. Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis.
Man-Ger Sun M; Pope JE
Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101822. PubMed ID: 36907732
[TBL] [Abstract][Full Text] [Related]
39. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.
Martinez-Taboada VM; Blanco R; Fito C; Pacheco MJ; Delgado-Rodriguez M; Rodriguez-Valverde V
Semin Arthritis Rheum; 2001 Feb; 30(4):257-71. PubMed ID: 11182026
[TBL] [Abstract][Full Text] [Related]
40. Polymyalgia rheumatica.
Lestico MR; Boh LE; Schuna AA
Clin Pharm; 1993 Aug; 12(8):571-80. PubMed ID: 8222521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
